Ana Gallego-Lleyda
Overview
Explore the profile of Ana Gallego-Lleyda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Miguel D, Gallego-Lleyda A, Martinez-Ara M, Plou J, Anel A, Martinez-Lostao L
Cancers (Basel)
. 2019 Dec;
11(12).
PMID: 31817469
Although TRAIL (TNF-related apoptosis-inducing ligand, also known as Apo2L) was described as capable of inducing apoptosis in transformed cells while sparing normal cells, limited results obtained in clinical trials has...
2.
Naval J, de Miguel D, Gallego-Lleyda A, Anel A, Martinez-Lostao L
Cancers (Basel)
. 2019 Apr;
11(4).
PMID: 30934872
(TNF)-related apoptosis-inducing ligand (TRAIL) is able to activate the extrinsic apoptotic pathway upon binding to DR4/TRAIL-R1 and/or DR5/TRAIL-R2 receptors. Structural data indicate that TRAIL functions as a trimer that can...
3.
Anel A, Gallego-Lleyda A, de Miguel D, Naval J, Martinez-Lostao L
Cells
. 2019 Feb;
8(2).
PMID: 30759880
T-cell mediated immune responses should be regulated to avoid the development of autoimmune or chronic inflammatory diseases. Several mechanisms have been described to regulate this process, namely death of overactivated...
4.
Gallego-Lleyda A, de Miguel D, Anel A, Martinez-Lostao L
Int J Mol Sci
. 2018 May;
19(5).
PMID: 29757258
Sarcomas are rare and heterogeneous cancers classically associated with a poor outcome. Sarcomas are 1% of the cancer but recent estimations indicate that sarcomas account for 2% of the estimated...
5.
de Miguel D, Gallego-Lleyda A, Ayuso J, Pejenaute-Ochoa D, Jarauta V, Marzo I, et al.
Cancer Lett
. 2016 Oct;
383(2):250-260.
PMID: 27725224
During the last years, a great effort has been invested into developing new TRAIL formulations with increased bioactivity, trying to overcome the resistance to conventional soluble TRAIL (sTRAIL) exhibited by...
6.
Bosque A, Dietz L, Gallego-Lleyda A, Sanclemente M, Iturralde M, Naval J, et al.
Oncotarget
. 2016 Apr;
7(20):29287-305.
PMID: 27086912
We have previously characterized that FasL and Apo2L/TRAIL are stored in their bioactive form inside human T cell blasts in intraluminal vesicles present in multivesicular bodies. These vesicles are rapidly...
7.
de Miguel D, Gallego-Lleyda A, Ayuso J, Erviti-Ardanaz S, Pazo-Cid R, Del Agua C, et al.
Nanotechnology
. 2016 Mar;
27(18):185101.
PMID: 27001952
Purpose: Non-small cell lung cancer (NSCLC) is one the types of cancer with higher prevalence and mortality. Apo2-Ligand/TRAIL is a TNF family member able to induce apoptosis in tumor cells...
8.
de Miguel D, Gallego-Lleyda A, Ayuso J, Pawlak A, Conde B, Ochoa I, et al.
Recent Pat Anticancer Drug Discov
. 2016 Mar;
11(2):197-214.
PMID: 26924736
Background: Apo2-ligand/TRAIL, a member of the TNF cytokine superfamily capable of inducing apoptosis on tumor cells while sparing normal cells, is a promising anti-tumor agent. However, about 50% of human...
9.
Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities
Martinez-Lostao L, de Miguel D, Al-Wasaby S, Gallego-Lleyda A, Anel A
Immunotherapy
. 2015 Aug;
7(8):883-2.
PMID: 26314314
The immune system plays a key role in cancer immune surveillance to control tumor development. The final goal is recognizing and killing transformed cells and consequently the elimination of the...
10.
de Miguel D, Gallego-Lleyda A, Anel A, Martinez-Lostao L
Leuk Res
. 2015 Apr;
39(6):657-66.
PMID: 25882551
Human Apo2-Ligand/TRAIL is a promising antitumor agent. Our group demonstrated that TRAIL was physiologically released to the extracellular medium inserted in lipid vesicles, known as exosomes. Recently we demonstrated that...